| Cardiovascular Risk Management |
1 |
1 |
| Biomarker |
0 |
0.99 |
| Heart Failure (HF) |
0 |
0.68 |
| Pulmonary Embolism |
0 |
0.64 |
| Deep Venous Thrombosis |
0 |
0.56 |
| Myocardial Infarction (MI) |
0 |
0.52 |
| Revenue and Practice Management |
0 |
0.44 |
| Atrial Fibrillation |
0 |
0.34 |
| Hypertension |
0 |
0.34 |
| Troponin |
0 |
0.34 |
| Coronary Artery Disease (CAD) |
0 |
0.3 |
| Grant |
0 |
0.25 |
| Hospital |
0 |
0.25 |
| Acute Coronary Syndrome |
0 |
0.24 |
| CT Scan |
0 |
0.19 |
| Artery |
0 |
0.17 |
| B-Type Natriuretic Peptide |
0 |
0.17 |
| In-Stent Restenosis |
0 |
0.15 |
| Care and Maintenance of Vision |
0 |
0.14 |
| Cataract |
0 |
0.14 |
| Healthcare and Medical Technology |
0 |
0.14 |
| Lipids Management |
0 |
0.14 |
| Percutaneous Coronary Intervention |
0 |
0.14 |
| Peripheral Artery Disease |
0 |
0.14 |
| Wound Management |
0 |
0.14 |
| A-Scan Biometry |
0 |
0.08 |
| Anatomy |
0 |
0.08 |
| Anticoagulation Therapy |
0 |
0.08 |
| Blood |
0 |
0.08 |
| Cardiovascular disease |
0 |
0.08 |
| Clinical Research |
0 |
0.08 |
| Financial Reimbursement |
0 |
0.08 |
| Heart |
0 |
0.08 |
| Infarction |
0 |
0.08 |
| Injury |
0 |
0.08 |
| Pandemic |
0 |
0.08 |
| Restenosis |
0 |
0.08 |
| Scan |
0 |
0.08 |
| Stent |
0 |
0.08 |